Altered Hepatic and Cerebral Lipid Mediator Pathways in Alzheimer’s Disease
Sitong Zhou(University of California Davis Medical Center), Izumi Maezawa(University of California Davis Medical Center), Nuanyi Liang(University of California, Davis), Geidy E. Serrano(Banner Sun Health Research Institute), John W. Newman(National Institutes of Health), Thomas G. Beach, Kyoungmi Kim(University of California Davis Medical Center), Kamil Borkowski(University of California, Davis), Bruce D. Hammock(UC Davis Comprehensive Cancer Center), Lee‐Way Jin(Neurological Surgery)
Cited by 0
Related Papers
Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease
|Nature Medicine|2002|768
<scp>A</scp>rizona <scp>S</scp>tudy of <scp>A</scp>ging and <scp>N</scp>eurodegenerative <scp>D</scp>isorders and <scp>B</scp>rain and <scp>B</scp>ody <scp>D</scp>onation <scp>P</scp>rogram
|Neuropathology|2015|502
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
|Cell|2022|495
Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: A critical review
|Journal of Autoimmunity|2015|461